Doc Number:

GLF-CEM-PV-06A [Old Doc no. 6.04]

ADVERSE DRUG REACTION (ADR)/ PRODUCT **QUALITY PROBLEM REPORT FORM**

Effective date: 20 January 2023

Revision: 2.0

(PUBLIC AND PRIVATE SECTOR) (Including Herbal Products)

SA	HPRA
	South African Health Products
	Regulatory Authority

Reporting Health Care Facility/Practice **Building A, Loftus Park** Facility/Practice 402 Kirkness Street, Arcadia, Pretoria District Tel Tel: (012) 501 0311 E-mail: adr@sahpra.org.za Province Fax **Patient Details** Patient File/Reference Number Date of Birth/Age Initials ПМ ПЕ Sex Race Weight (kg) Height (cm) Pregnant? \square N \square Y □Unk Estimated Gestational Age at time of reaction Allergies Suspect Medicine(s) [Medicines suspected to have caused the ADR], Concomitant [Other medicines taken together with the suspect medicine(s)] OR Interacting [Other medicines taken together with the suspect medicine(s) and may have interacted with the suspect medicine(s)] [Including over-thecounter and herbal products]. Suspect or Concomitant or Date Trade Name [Active Ingredient Dose (mg) and Date Batch **Expiry** Interacting Route Started/ Reason for use if Trade Name is unknown] Stopped Interval Number Date Medicines Taken Given (Please tick the applicable box ☐ Suspect ☐ Concomitant ☐ Interacting ☐ Suspect ☐ Concomitant ☐ Interacting ☐ Suspect ☐ Concomitant \square Interacting ☐ Suspect ☐ Concomitant ☐ Interacting ☐ Suspect ☐ Concomitant □ Interacting ☐ Suspect ☐ Concomitant ☐ Interacting Adverse Drug Reaction/Product Quality Problem Date and time of onset of reaction Date reaction resolved Please describe Adverse Event/Product Quality Problem: (kindly add as much clinical information as possible) Adverse event seriousness criteria (Tick Intervention (Tick all that apply) Patient Outcomes (Tick all that apply) all that apply) ☐ No intervention ☐ ADR recovered/resolved ☐ Resulted in death Date of death: ☐ Intervention unknown ☐ Recovering/resolving ☐ Patient counselled/non-medical treatment $\hfill\square$ Not recovered/not resolved $\hfill\square$ Patient hospitalised or hospitalisation ☐ Discontinued suspect drug; Replaced with: \square Recovered with sequelae prolonged ☐ Life threatening ☐ Decreased suspect drug dosage; **New Dose**: ☐ ADR resolved after suspect medicine was ☐ Impairment/disability ☐ Treated ADR - with: stopped: \(\D\ N \\ \D\ Y \) ☐ Congenital anomaly/ birth defect ☐ Referred to hospital: Hospital name_ \square ADR reappeared after restarting suspect \square Other intervention (e.g., dialysis): drug/similar drug (rechallenge): ☐ Other medically important condition □N □Y □Not done □Unknown **Laboratory Results Additional Laboratory Results Lab Test Test Result Test Date Lab Test Test Result Test Date** Co-morbidities/Other Medical Condition(s) Reported by E-mail Name Designation □ Nurse □ Pharmacist □ Doctor □ Other: Telephone Date reported: Signature

GLF-CEM-PV-06A_v2 Page 1 of 2

THIS ADR REPORT IS NOT A CONFIRMATION THAT THE REPORTER OR THE SUSPECT MEDICINE(S) CAUSED THE ADR

ADVICE ABOUT VOLUNTARY REPORTING

Report adverse experiences with:

- medications (drugs, vaccines and biologicals)
- complementary / alternative medicines (including traditional, herbal remedies, etc.)

Please report especially:

- adverse drug reactions to newly marketed products
- serious reactions and interactions with all products
- adverse drug reactions which are not clearly reflected in the package insert.

Report Product Quality Problems such as:

- suspected contamination
- questionable stability
- defective components
- poor packaging or labelling
- therapeutic failures

Report even if:

- you're not certain the product caused the event
- · you don't have all the details

Report Product Quality Problems via:

- phone: 0800 204 307
- SAHPRA portal: <u>Complaints Relating to Medicine and</u> Medical Devices - SAHPRA

Adverse Events Following Immunisation:

• phone: 0800 02 9999

• email: <u>AEFI@health.go.za</u>

Other reporting tools available at SAHPRA include:

Med Safety Application

The Med Safety Application is a mobile application designed for the public and healthcare professionals to report suspected ADRs/adverse event following immunisations (AEFIs). It is the preferred reporting tool by SAHPRA and allows for a seamless electronic submission of ADR/AEFI reports directly from the source into SAHPRA's reporting systems. The app can be downloaded onto a smart mobile phone directly from the SAHPRA website, https://medsafety.sahpra.org.za. For more reporting channels please visit SAHPRA website, https://www.sahpra.org.za.

CONSENT CLAUSE

By the signature above, the reporter hereby provides consent to the processing of personal information provided for the purpose of reporting a suspected adverse reaction. The reporter acknowledges that this information may be used a) to access all medical and clinical records for the purpose of gathering additional information for a clinical meaningful data, when required; b) in the generation of statistics; and c) to make policy decisions relating to safe use of medicines.

SAHPRA Vigilance unit undertakes to collate the personal information contained in this form and collected during the process of reporting of suspected adverse drug reaction in a manner that adheres to the Protection of Personal Information Act, so that your personal data is processed fairly, lawfully and transparently, adequate, relevant, and limited to what is necessary, processed for specific and legitimate purposes, accurate and kept up to date where necessary, kept in an identifiable form no longer than necessary for the purpose, processed securely . SAHPRA has put appropriate technical and organisational measures to safeguard your information. The information will not be stored for any longer than is necessary to achieve the purpose for which it was collected, unless SAHPRA Vigilance unit has a lawful basis to do so. If the reporter wishes to access and/or rectify their personal information, they may do so by contacting SAHPRA Vigilance unit at 012 501 0311 or via email: adr@sahpra.org.za.

Confidentiality: Identities of the reporter and patient will remain strictly confidential.

Your support of the South African Health Products Regulatory Authority's adverse drug reaction monitoring programme is much appreciated. Information supplied by you will contribute to the improvement of medicine safety and therapy in South Africa.

GLF-CEM-PV-06A v2 Page 2 of 2